JOHNSON & JOHNSON is 138.2x more valuable than Dianthus Therapeutics, Inc. /DE/ by market capitalization ($574.10 B vs $4.15 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | DNTH | JNJ |
|---|---|---|
| Market cap | $4.15 B | $574.10 B |
| US-listed rank | #1546 | #20 |
| Revenue (latest FY) | $2.04M | $94.19B |
| Net income (latest FY) | -$162.34M | $26.80B |
| Net margin | -7973.3% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 624 | 984 |
JOHNSON & JOHNSON is 138.2x more valuable than Dianthus Therapeutics, Inc. /DE/ by market capitalization ($574.10 B vs $4.15 B).
In their latest fiscal years, Dianthus Therapeutics, Inc. /DE/ reported $2.04M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Dianthus Therapeutics, Inc. /DE/ and JOHNSON & JOHNSON, or browse the full rankings.